Dynamic Technology Lab Private Ltd Sells 4,403 Shares of Illumina, Inc. (NASDAQ:ILMN)

Dynamic Technology Lab Private Ltd cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 55.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,547 shares of the life sciences company’s stock after selling 4,403 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Illumina were worth $463,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Freemont Management S.A. bought a new position in shares of Illumina during the third quarter valued at $1,565,000. Cetera Advisors LLC bought a new position in shares of Illumina in the first quarter valued at about $610,000. Weybosset Research & Management LLC raised its holdings in shares of Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in shares of Illumina by 176.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after buying an additional 4,579 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Illumina by 3.6% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after buying an additional 13,725 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on ILMN. StockNews.com began coverage on Illumina in a report on Thursday, August 29th. They issued a “buy” rating for the company. Leerink Partners lifted their price objective on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. UBS Group lifted their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research report on Tuesday, November 12th. Finally, Scotiabank decreased their target price on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Trading Down 0.1 %

NASDAQ ILMN opened at $144.15 on Friday. The stock has a market capitalization of $22.86 billion, a price-to-earnings ratio of -14.47 and a beta of 1.13. The stock’s 50 day moving average price is $141.88 and its two-hundred day moving average price is $125.88. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a 52 week low of $99.23 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.33 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.